Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders

Molecular Psychiatry

Volumn 7, Issue 9, 2002, Pages 985-994

  Webster, M J ^a   Knable, M B ^a   O'Grady, J ^a   Orthmann, J ^a   Weickert, C S ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Depression; Frontal cortex; Glucocorticoid receptors; Hippocampus; Schizophrenia; Temporal cortex

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MESSENGER RNA;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DISEASE SEVERITY; DOWN REGULATION; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; GENETIC HETEROGENEITY; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; MALE; MENTAL DISEASE; MOOD DISORDER; NEGATIVE FEEDBACK; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA HYBRIDIZATION; SCHIZOPHRENIA; STRESS; SURGICAL ANATOMY; TEMPORAL CORTEX; BRAIN LEVEL; COMPARATIVE STUDY; FRONTAL LOBE; GENE EXPRESSION; GENETICS; MAJOR DEPRESSION; MIDDLE AGED; NORTHERN BLOTTING; PHYSIOLOGY; TEMPORAL LOBE;

ADULT; BIPOLAR DISORDER; BLOTTING, NORTHERN; BRAIN CHEMISTRY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FRONTAL LOBE; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 0036428858     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001139     Document Type: Article

References (94)

1. Pariante CM, Nemeroff CB, Miller AH. Glucocorticoid receptors in depression. Isr J Med Sci 1995; 31: 705-712.
2. Baxter JD, Terryll JB. The adrenal cortex. In: Felig P, Baxter JD, Broadus AE (eds). Endocrinology and Metabolism. McGraw-Hill: New York, 1987, pp 511-650.
3. Swanson LW, Sawchenko PE, Lind RW, Regulation of multiple peptides in CRF parvocellular neurosecretory neurons: Implications for the stress response. Prog Brain Res 1986; 68: 169-190.
4. Fuxe K, Cintra A, Tanganelli S, Von Euler G, Finnman U-B, Lundgren K et al. Integration of humoral and neuronal signals in neuroendocrine regulation, focus on interaction of glucocorticoids with central neuropeptide and monoamine neurotransmission. In: Casanueva FF, Dieguez C (eds). Recent Advances in Basic and Clinical Neuroendocrinology. Elsevier Science Pub: Amsterdam, 1989, pp 109-126.
5. Fuxe K, Cintra A, Chadi G, Gustafsson J-A, Agnati LF. Central glucocorticoid receptors and neuronal plasticity. Meth Neurosci 1994; 22; 272-382.
6. Cintra A, Bhatnagar M, Chadi G, Tinner B, Lindberg J, Gustafsson J-A et al. Glial and neuronal glucocorticoid receptor immunoreactive cell populations in developing, adult, and aging brain. Ann NY Acad Sci 1994; 736: 42-63.
7. De Nicola AF, Ferrini M, Gonzalez SL, Deniselle MCG, Grillo CA, Piroli G et al. Regulation of gene expression by corticoid hormones in the brain and spinal cord. J Steroid Biochem Mol Biol 1998; 65: 253-272.
8. Steckler T, Holsboer F, Reul JMHM. Glucocorticoids and depression. Bailliere's Clin Endocrinol Metab 1999; 13: 597-614.
9. Gibbons JL. Cortisol secretion rate in depressive illness. Arch Gen Psychiatry 1964; 10: 572-575.
10. Carroll BJ, Feinburg M, Greden JF, Haskett RF, James NM, Steiner M, Tarika J. Diagnosis of endogenous depression: Comparison of clinical, research, and neuroendocrine criteria. J Affect Disord 1980; 2: 177-194.
11. Beck-Friis J, Ljunggren JG, Thoren M, von Rosen D, Kjellman BF, Wetterberg L. Melatonin, cortisol, and ACTH in patients with major depressive disorder and healthy humans with special reference to the outcome of the daxamethasone suppression test. Psychoneuroendocrinology 1985; 10: 173-186.
12. Lesch KP, Laux G, Schulte HM, Pfuller H, Beckmann H. Corticotropin and cortisol response to human CRH as a probe for HPA system integrity in major depressive disorder. Psychiatry Res 1988; 24: 25-34.
13. Owens MJ, Nemeroff CB. The Role of Corticotropin-releasing Factor in the Pathophysiology of Affective and Anxiety Disorders: Laboratory and Clinical Studies: Corticotropin Releasing Factor (Ciba Foundation Symposium 172). Wiley: Chichester, UK, 1993, pp 296-316.
14. Rubin RT, Phillips JS, McCracken JT, Sadow TF. Adrenal gland volume in major depression: Relationship to basal and stimulated pituitary-adrenal cortical axis function. Biol Psychiatry 1996; 40: 89-97.
15. 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547-573.
16. Linkowsky P, von Bardeleben U, Gerken A, Stalla GK, Muller OA. The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry 1994; 51: 616-624.
17. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet seretonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry 1999; 45: 1433-1439.
18. Barden N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiat Neurosci 1999; 24: 25-39.
19. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC et al. Distribution of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nature Genet 1999; 23: 99-103.
20. Gormley GJ, Lowy MT, Reder AT, Hospelhorn VD, Antel JP, Meltzer HY, Glucocorticoid receptors in depression: Relationship to the dexamethasone suppression test. Am J Psychiatry 1985; 142: 1278-1284.
21. Sallee FR, Nesbit L, Dougherty D, Hilal R, Nandagopal VS, Sethuramen G. Lymphocyte glucocorticoid receptor: Predictor of sertraline response in adolescent major depressive disorder (MDD). Psychopharmacol Bull 1995; 31: 339-345.
22. Walley LJ, Borthwick N, Copolov D, Dick H, Christie JE, Fink G. Glucocorticoid receptors and depression. Br Med J 1986; 292: 859-861.
23. Yehuda R, Boisoneau D, Mason JW, Giller EL. Gluciocorticoid receptor number and cortisol excretion in mood, anxiety and psychotic disorders. Biol Psychiatry 1993; 34: 18-25.
24. Sapolsky RM, McEwen BS. Down-regulation of neural corticosterone receptors by corticosterone and dexamethasone. Brain Res 1985; 339: 161-165.
25. Zoli M, Agnati F, Ferraguti F, Biagini G, Cintra A, Gustafsson J-A. Long-lasting reduction of glucocorticoid receptor immunoreactivity in the hippocampal field CA1 but not in the dentate gyrus after neonatal treatment with corticosterone in the rat. Acta Physiol Scand 1990; 138: 577-579.
26. Meaney MJ, Diorio J, Francis D, Widdowson J, LaPlante P, Caldji C et al. Early environmental regulation of forebrain glucocorticoid receptor gene expression: Implications for adrenocortical responses to stress. Dev Neurosci 1996; 18: 49-72.
27. Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992; 55: 621-626.
28. Przegalinski E, Budziszewska B, Siwanowicz J, Jaworska L. The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology 1993; 32: 1397-1400.
29. Torrey EF, Webster M, Knable M, Johnson N, Yolken RH. The Stanley Foundation brain collection and Neuropathology Consortium. Schizophr Res 2000; 44: 151-155.
30. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-641.
31. Whitfield Jr HJ, Brady LS, Smith MA, Mamalaki E, Fox RJ, Herkenham M. Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: A detailed protocol. Cell Mol Neurobiol 1990; 10: 145-157.
32. Rajkowska G, Golman-Rakic P. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 1995; 5: 307-322.
33. Insausti R, Tunon T, Sorbreviela T, Insausti AM, Gonzalo LM. The human entorhinal cortex: A cytoarchitectonic analysis. J Comp Neurol 1995; 355: 171-198.
34. Bronnegard M, Arner P, Hellstrom L, Akner G, Gustafsson JA. Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. Endocrinology 1990; 127: 1689-1696.
35. Whorwood CB, Franklyn JA, Sheppard MC, Stewart PM. Tissue localization of 11 beta-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor. J Steroid Biochem Mol Biol 1992; 41: 21-28.
36. Sousa RJ, Tannery NH, Lafer EM. In situ hybridization mapping of glucocorticoid receptor messenger ribonucleic acid in rat brian. Mol Endocrinol 1989; 3: 481-494.
37. Kitraki E, Alexis MN, Papalopoulou M, Stylianopoulou F. Glucocorticoid receptor gene expression in the embryonic rat brain. Neuroendocrinology 1996; 63: 305-317.
38. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method. J Comp Neurol 1998; 392: 402-412.
39. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psych 1999; 45: 1085-1098.
40. Ongur D, Drevets WC, Price J. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci 1998; 95: 13290-13295.
41. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: The evidence and implications. Brain Res Bull 2001; 55: 585-595.
42. Cotter DR, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulated cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-553.
43. Cotter DR, Mackay D, Chana G, Beasley C, Landau S, Everall I. Reduced neuronal size and glial cell density in Area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386-410.
44. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial Density in the Prefrontal Cortex Area 9 in Schizophrenia and Mood Disorders: A Study of Brain Collection from the Stanley Foundation Neuropathology Consortium. (Submitted).
45. Seckl JR, Dickson KL, Yates C, Fink G. Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus. Brain Res 1991; 561: 332-337.
46. Suddath RL, Casanova MD, Goldberg TE, Daniel DG, Kelsoe JR, Weinberger DR. Temporal lobe pathology in schizophrenia: A quantitative magnetic resonance imaging study. Am J Psychiatry 1989; 146: 464-472.
47. Bogerts B, Falkai P, Haupts M. Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Schizophrenia Res 1990; 3: 295-301.
48. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R et al. Postmortem evidence of structural brain changes in schizophrenia. Difference in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry 1986; 43: 36-42.
49. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-3913.
50. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neuroscience 1999; 19: 5034-5043.
51. Jeste DV, Lohr JB. Hippocampal pathologic findings in schizophrenia. A morphometric study. Arch Gen Psychiatry 1989; 46: 1019-1024.
52. Heckers S, Heinsen H, Geiger B, Beckman H. Hippocampal neuron number in schizophrenia. A stereological study. Arch Gen Psychiatry 1991; 48: 1002-1008.
53. Eastwood SL, Harrison PJ. Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: A study of complexin mRNAs. Mol Psychiatry 2000; 5: 425-432.
54. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocrinol Rev 1986; 7: 284-301.
55. Reagen L, McEwen B. Controversies surrounding glucocorticoid-mediated cell death in the hippocampus. J Chem Neuroanat 1997; 13: 149-158.
56. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psych 2000; 57: 925-935.
57. Gould E, McEwen BS, Tanapat P, Galea LAM, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997; 17: 2492-2498.
58. Gould E, Tanapat P. Stress and hippocampal neurogenesis. Biol Psychiatry 1999; 46: 1472-1479.
59. Shi B, Mocchetti I. Dexamethasone induces TrkA and p75NTR immunoreactivity in the cerebral cortex and hippocampus. Proc Natl Acad Sci USA 1998; 95: 3204-3208.
60. Chao HM, McEwen BS. Glucocorticoids and the expression of mRNAs for neurotrophins, their receptors and GAP-43 in the rat hippocampus. Mol Brain Res 1994; 26: 271-276.
61. Chao HM, Sakai RR, Ma LY, McEwen BS. Adrenal steroid regulation of neurotrophic factor expression in the rat hippocampus. Endocrinology 1998; 139: 3112-3118.
62. Fujikawa T, Soya H, Fukuoka H, Alam KSM, Yoshizato H, McEwen BS, Nakashima K. A biphasic regulation of receptor mRNA expression for growth hormone, glucocorticoid and mineral-corticoid in the rat dentate gyrus during acute stress. Brain Res 2000; 874: 186-193.
63. Brouha AK, Shannon Weickert C, Hyde TM, Herman MM, Murray AM, Bigelow LB et al. Reductions in brain derived neurotrophic factor mRNA in the hippocampus of patients with schizophrenia. SFN Abstr 1996; 22: 1680.
64. Eastwood SL, Harrison PJ. Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia. Neuroscience 1998; 86: 437-448.
65. Webster, MJ, Shannon Weickert C, Herman MM, Hyde TM, Kleinman J. Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia. Schizophr Res 2001; 49: 61-70.
66. Schramm M, Falkai P, Feldmann N, Knable MB, Bayer TA. Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia. Neurosci Lett 1998; 257: 65-68.
67. Selemon LD, Rajkowska G, Goldman-Rakic PS. Adnormally high neuronal density in the schizophrenic cortex: A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995; 52: 805-818.
68. Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience 1995; 69: 339-343.
69. Eastwood SL, Harrison PJ. Detection and quantitation of hippocampal synaptophysin messenger RNA in schizophrenia using autoclaved, formalin-fixed paraffin embedded sections. Neuroscience 1999; 93: 99-109.
70. Eastwood SL, Burnet PWJ, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995; 66: 309-319.
71. Vawter MP, Howard AL, Hyde TM, Klienman JE, Freed WJ. Alterations of hippocampal secreted N-CAM in bipolar disorder and synaptophysin in schizophrenia. Mol Psychiatry 1999; 4: 467-475.
72. Shannon-Weickert C, Webster MJ, Hyde TH, Herman MM, Bachus SE, Bali G et al. Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cereb Cortex 2001; 11: 136-147.
73. Glanz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: Regional and diagnostic specificity. Arch Gen Psychiatry 1997; 54: 660-669.
74. Glanz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000; 57: 65-73.
75. Rosoklija G, Toomayan G, Ellis SP, Kielp J, Mann JJ, Latov N et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: Preliminary findings. Arch Gen Psychiatry 2000; 57: 349-356.
76. Nelson MD, Saykin AJ, Flashman LA, Riordan JH. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study. Arch Gen Psychiatry 1998; 55: 433-440.
77. Velakoulis D, Pantelis C, McGorry PD, Dudgeon P, Brewer W, Cook M et al. Hippocampal volume in first-episode psychoses and chronic schizophrenia. A high-resolution magnetic resonance imaging study. Arch Gen Psychiatry 199; 56: 133-140.
78. Gur RE, Cowell PE, Latshaw A, Turetsky BI, Grossman RI, Arnold SE et al. Reduced orbital and prefrontal gray matter volumes in schizophrenia. Arch Gen Psychiatry 200; 57: 761-768.
79. Gur RE, Turetsky BI, Cowell PE, Finkelman C, Maany V, Grossman RI et al. Temporolimbic volume reductions in schizophrenia. Arch Gen Psychiatry 2000; 57: 769-775.
80. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157: 16-25.
81. Staal WG, Pol HEH, Schnack HG, Hoogendoorn MLC, Jellema K, Kahn RS. Structural brain abnormalities in patients with schizophrenia and their healthy sibling. Am J Psychiatry 2000; 157: 416-421.
82. Hirayasu Y, Tanaka S, Shenton ME, Salisbury DF, DeSantis MA, Levitt JJ et al. Prefrontal gray matter volume reduction in first episode schizophrenia. Cereb Cortex 2001; 11: 374-381.
83. Makino S, Smith MA, Gold PW. Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamus paraventricular nucleus during repeated stress: Association with reduction in glucocorticoid receptor mRNA levels. Endocrinology 1995; 136: 3299-3309.
84. Pepin MC, Beaulieu S, Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol Brain Res 1989; 6: 77-83.
85. Beaulieu S, Barden N. Antidepressant, serotonergic and glucocorticoid modulation of GR mRNA in hypothalamic neurons. Neuroendocrinol Lett 1987; 9: 186.
86. Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, Ogren SO et al. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. J Neural Transm 1988; 73: 191-203.
87. Peiffer A, Veilleux S, Barden N. Antidepressants and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991; 16: 505-515.
88. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gone expression in cultured rat hippocampal neurons. J Neuroendocrinol 1999; 11: 887-895.
89. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 20001; 49: 391-404.
90. Selemon LD, Lidow MS, Goldman-Rakic PS. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry 1999; 46: 161-172.
91. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2000; 48: 1121-1132.
92. Lupien SJ. Stress and schizophrenia: The importance of cognition. Biol Psychiatry 2000; 48: 1119-1120.
93. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
94. Weinberger DR. Anteromedial temporal-prefrontal connectivity: A functional neuroanatomical system implicated in schizophrenia. In: Carroll BJ, Barrett JE (eds). Psychopathology and the Brain. Raven Press: New York, 1991, pp 25-43.